Overall rank by patents
#5,969
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Pangu Biopharma Limited
USPTO PatentsView assignee record — 57 granted patents across 8 technology areas, active 2015–2021. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).
57
Total patents granted
8
CPC technology areas
12.6
Avg claims per patent
-88%
5-year filing velocity
The verdict
Pangu holds 57 US patents across 8 technology areas — rank #5,969 of 50,000 tracked assignees.
- #5,969
- of 50,000 US assignees by volume
- Top 62%
- by Innovation Score (31.6/100)
- 12.6
- avg claims per patent
- -88%
- filing velocity, last 5 yrs
Portfolio overview
Pangu BioPharma Limited has been granted 57 US utility patents between 2015 and 2021, placing Pangu BioPharma Limited at rank #5,969 across all assignees tracked by PlainPatent. This portfolio spans 8 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.6 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a Foreign Corporation, Pangu BioPharma Limited is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 31.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 6 grants, compared with 51 in the 2015–2019 window — a -88% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Pangu BioPharma Limited's 12.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 8 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Pangu BioPharma Limited against peers pursuing similar technology classes.
How does Pangu compare?
Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Pangu Biopharma ◀ 57
Pangu BioPharma Limited
57 patents
What this shows Pangu holds 57 patents — placing it at rank #5,969 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
Pangu's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
32 Top 62% higher than 38% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2015–2021
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 17 | 29.8% |
| 2016 | 11 | 19.3% |
| 2017 | 12 | 21.1% |
| 2018 | 4 | 7.0% |
| 2019 | 7 | 12.3% |
| 2020 | 5 | 8.8% |
| 2021 | 1 | 1.8% |
Which technologies does Pangu BioPharma Limited patent most?
Top 8 of 8 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Declining
Frequently Asked Questions
How many patents does Pangu BioPharma Limited hold?
Pangu BioPharma Limited holds 57 US granted patents filed between 2015 and 2021, spanning 8 technology areas.
What is Pangu BioPharma Limited's Innovation Score?
Pangu BioPharma Limited has an Innovation Score of 31.6 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Pangu BioPharma Limited focus on?
Pangu BioPharma Limited's top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 57 patents. The company has filed patents in 8 CPC subclasses total.
Is Pangu BioPharma Limited's patent filing rate increasing or decreasing?
Pangu BioPharma Limited's recent filing velocity is -88% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Pangu BioPharma Limited's patents?
Pangu BioPharma Limited's patents average 12.6 claims each. This falls within the standard range, providing solid legal coverage.
How is the Pangu BioPharma Limited patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Learn More
How to use this portfolio
Pangu's 57 grants land it in the top 62% by Innovation Score — but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance — Pangu ranks #5,969 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C12N — see who else leads that technology area. C12N leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity — not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Explore the patent dataset
C12N technology
Pangu BioPharma Limited's primary CPC class — all holders and yearly trends
Top 50 patent holders
See where Pangu BioPharma Limited ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Data sources used on this page
- USPTO PatentsView — the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
- Cooperative Patent Classification (CPC) — the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
- USPTO Patent Public Search — the official interface to verify the status of any individual patent. ppubs.uspto.gov
